Cover Image
市場調查報告書

開放性青光眼 : 開發中產品分析

Open-Angle Glaucoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229787
出版日期 內容資訊 英文 123 Pages
訂單完成後即時交付
價格
Back to Top
開放性青光眼 : 開發中產品分析 Open-Angle Glaucoma - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 123 Pages
簡介

開放性青光眼又稱為廣角青光眼,是最常見的青光眼。雖然眼睛的構造看來正常,但眼中的液體卻漸漸無法適切流過小柱網。一般的症狀會二眼一起發生,周圍視野會漸漸失明,導致視野愈來愈狹窄。容易罹患的危險因子有年齡、青光眼的家族病史、長期使用皮質類固醇、眼壓上升等。

本報告提供開放性青光眼治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

開放性青光眼概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • Aerie Pharmaceuticals, Inc.
  • Allergan Plc
  • Amakem NV
  • Bausch & Lomb Incorporated
  • F. Hoffmann-La Roche Ltd.
  • Glaukos Corporation
  • Inotek Pharmaceuticals Corporation
  • Isarna Therapeutics GmbH
  • 興和
  • Laboratoires Thea S.A.
  • Laboratorios Sophia S.A. de C.V.
  • Lee's Pharmaceutical Holdings Limited
  • Lexicon Pharmaceuticals, Inc.
  • Ocular Therapeutix, Inc.
  • 大塚集團
  • Oxford BioMedica Plc
  • Sanofi
  • 參天製藥
  • 千壽製藥
  • Sun Pharma Advanced Research Company Ltd.
  • Sylentis S.A.U.
  • ViSci Ltd.

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8409IDB

Summary

Global Markets Direct's, 'Open-Angle Glaucoma - Pipeline Review, H2 2016', provides an overview of the Open-Angle Glaucoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Open-Angle Glaucoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma
  • The report reviews pipeline therapeutics for Open-Angle Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Open-Angle Glaucoma therapeutics and enlists all their major and minor projects
  • The report assesses Open-Angle Glaucoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Open-Angle Glaucoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Open-Angle Glaucoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Open-Angle Glaucoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Open-Angle Glaucoma Overview
  • Therapeutics Development
    • Pipeline Products for Open-Angle Glaucoma - Overview
    • Pipeline Products for Open-Angle Glaucoma - Comparative Analysis
  • Open-Angle Glaucoma - Therapeutics under Development by Companies
  • Open-Angle Glaucoma - Therapeutics under Investigation by Universities/Institutes
  • Open-Angle Glaucoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Open-Angle Glaucoma - Products under Development by Companies
  • Open-Angle Glaucoma - Products under Investigation by Universities/Institutes
  • Open-Angle Glaucoma - Companies Involved in Therapeutics Development
    • Aerie Pharmaceuticals, Inc.
    • Allergan Plc
    • Amakem NV
    • Bausch & Lomb Incorporated
    • F. Hoffmann-La Roche Ltd.
    • Glaukos Corporation
    • Inotek Pharmaceuticals Corporation
    • Isarna Therapeutics GmbH
    • Kowa Company, Ltd.
    • Laboratoires Thea S.A.
    • Laboratorios Sophia S.A. de C.V.
    • Lee's Pharmaceutical Holdings Limited
    • Lexicon Pharmaceuticals, Inc.
    • Ocular Therapeutix, Inc.
    • Otsuka Holdings Co., Ltd.
    • Oxford BioMedica Plc
    • Sanofi
    • Santen Pharmaceutical Co., Ltd.
    • Senju Pharmaceutical Co., Ltd.
    • Sun Pharma Advanced Research Company Ltd.
    • Sylentis S.A.U.
    • ViSci Ltd.
  • Open-Angle Glaucoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (bimatoprost + brimonidine tartarate + timolol maleate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (bimatoprost + timolol maleate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (carteolol hydrochloride + latanoprost) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (latanoprost + netarsudil mesylate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (latanoprost + timolol maleate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (latanoprost + trabodenoson) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMA-0076 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotides to Inhibit P16INK4a for Primary Open-Angle Glaucoma (POAG) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bamosiran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bimatoprost - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bimatoprost SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DE-117 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • decorin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Glaucoma-GT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISTH-0036 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latanoprost - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latanoprost - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latanoprost SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latanoprost SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latanoprostene bunod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levobetaxolol hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LX-7101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAN-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGV-354 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • netarsudil mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OPA-6566 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRO-067 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-4929 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ripasudil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-5093151 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-366234 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Sepetaprost - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SNJ-1656 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trabodenoson - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • travoprost - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • travoprost SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • travoprost XR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Open-Angle Glaucoma - Dormant Projects
  • Open-Angle Glaucoma - Discontinued Products
  • Open-Angle Glaucoma - Product Development Milestones
    • Featured News & Press Releases
      • Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting
      • Apr 11, 2016: Inotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension
      • Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting
      • Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week
      • Mar 10, 2010: Qlt Announces Phase II Clinical Trial Results And Development Plans For The Punctal Plug Delivery System
      • Jul 28, 2009: Qlt Announces Interim Data From A Phase II Clinical Trial And A Device Study For A Punctal Plug Drug Delivery System
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Open-Angle Glaucoma, H2 2016
  • Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Open-Angle Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016
  • Open-Angle Glaucoma - Pipeline by Allergan Plc, H2 2016
  • Open-Angle Glaucoma - Pipeline by Amakem NV, H2 2016
  • Open-Angle Glaucoma - Pipeline by Bausch & Lomb Incorporated, H2 2016
  • Open-Angle Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Open-Angle Glaucoma - Pipeline by Glaukos Corporation, H2 2016
  • Open-Angle Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H2 2016
  • Open-Angle Glaucoma - Pipeline by Isarna Therapeutics GmbH, H2 2016
  • Open-Angle Glaucoma - Pipeline by Kowa Company, Ltd., H2 2016
  • Open-Angle Glaucoma - Pipeline by Laboratoires Thea S.A., H2 2016
  • Open-Angle Glaucoma - Pipeline by Laboratorios Sophia S.A. de C.V., H2 2016
  • Open-Angle Glaucoma - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
  • Open-Angle Glaucoma - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016
  • Open-Angle Glaucoma - Pipeline by Ocular Therapeutix, Inc., H2 2016
  • Open-Angle Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Open-Angle Glaucoma - Pipeline by Oxford BioMedica Plc, H2 2016
  • Open-Angle Glaucoma - Pipeline by Sanofi, H2 2016
  • Open-Angle Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016
  • Open-Angle Glaucoma - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016
  • Open-Angle Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
  • Open-Angle Glaucoma - Pipeline by Sylentis S.A.U., H2 2016
  • Open-Angle Glaucoma - Pipeline by ViSci Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Open-Angle Glaucoma - Dormant Projects, H2 2016
  • Open-Angle Glaucoma - Dormant Projects (Contd..1), H2 2016
  • Open-Angle Glaucoma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Open-Angle Glaucoma, H2 2016
  • Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top